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Levels of Protein C and Protein S, Tissue-Plasminogen
Activator, and Fibrinogen During
Cardiopulmonary Bypass
Aim: The exposure of blood to foreign surfaces during cardiopulmonary bypass (CPB) leads to an activation
of the coagulation system. The goal of this study was to evaluate the levels of protein C and protein S, tissueplasminogen activator (t-PA) and fibrinogen before, during and after CPB.
Materials and Methods: Thirty-three patients undergoing elective coronary artery bypass grafting (CABG)
and 11 patients undergoing non-cardiac surgery (control group) were included in this study. Blood samples
were taken at different time intervals preoperatively, before, during and after CPB, and in the postoperative
period. Protein C and protein S, t-PA and fibrinogen levels were measured before, during and after CPB.
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Results: Protein C, protein S and fibrinogen levels were decreased during CPB (p<0.05). As a marker of
hyperfibrinolysis, levels of t-PA were higher during CPB, which might suggest ongoing subclinical hemostatic
activation associated with CABG. Before release of aortic cross clamp, t-PA level had increased eight-fold. tPA levels remained elevated throughout CPB and into the early postoperative period. Protein C, protein S and
fibrinogen levels remained decreased throughout CPB, and the decrease continued until the end of CPB. There
was no difference in the hemostatic markers in the control group. There was a statistically significant
difference between the groups (p<0.01) before the induction of anesthesia and during CPB for all parameters
(p<0.01).
Conclusions: As a marker of hyperfibrinolysis, levels of t-PA were increased during CPB and remained
elevated in the early postoperative period. Protein C, protein S and fibrinogen levels were decreased during
CPB. These results showed that thrombin generation is increased during CPB.
Key Words: Cardiopulmonary bypass, protein C and protein S systems, tissue plasminogen activator,
fibrinogen

Kardiyopulmoner Bypass Esnas›nda Protein-C ve Protein-S, Doku Plazminojen
Aktivatörü ve Fibrinojen Düzeyleri
Amaç: Kardiyopulmoner bypass (KPB) esnas›nda kan›n yabanc› yüzeylerle temas›, koagulasyon sisteminin
aktive olmas›na yol açar. Bu çal›ﬂman›n amac› KPB öncesinde, esnas›nda ve sonras›nda protein C (PC) ve
protein S (PS), doku plazminojen aktivatörü (t-PA) ve fibrinojen (F) düzeylerini de¤erlendirmektir.
Yöntem ve gereç: Bu çal›ﬂmaya elektif koroner arter bypass cerrahisi (KABC) yap›lan 33 hasta ve kardiyak
cerrahi yap›lmayan 11 hasta (kontrol grubu) al›nd›. Kan örnekleri ameliyat öncesi, KPB öncesi, esnas› ve
sonras›nda ve ameliyat sonras› olmak üzere farkl› zamanlarda al›nd›. KPB öncesinde, esnas›nda ve sonras›nda
PC ve PS, t-PA ve F düzeyleri ölçüldü.
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Bulgular: KPB esnas›nda PC ve PS ve F düzeyleri azald› (p < 0.05). Bir hiperfibrinolizis markeri olan t-PA
düzeyleri, KPB esnas›nda daha yüksekti. Bu durum KABC ile birlikte subklinik hemostatik aktivasyonun
geliﬂti¤ini gösterebilir. KPB baﬂlang›c›nda aorttaki kros klemp kald›r›lmadan önce t-PA düzeyi 8 kat artt›, KPB
esnas›nda ve ameliyat sonras› erken dönemde ise yüksek kald›. KPB süresince PC ve PS ve F düzeyleri azald›
ve bu düﬂüﬂ KPB’›n sonuna kadar devam etti. Kontrol grubunda hemostatik markerler aras›nda anlaml› bir fark
yoktu. Tüm parametreler için gruplar aras›nda anestezi indüksiyonundan önce ve KPB esnas›nda istatistiki
olarak önemli fark vard› (p< 0.01).
Sonuç: Bir hiperfibrinolizis markeri olan t-PA düzeyleri, KPB esnas›nda yüksekti ve ameliyat sonras› erken
dönemde de yüksek kald›. Protein C ve PS ve F düzeyleri KPB süresince azald›. Bu sonuçlar trombin
generasyonunun KPB esnas›nda artt›¤›n› göstermektedir.
Anahtar Sözcükler: Kardiyopulmoner bypass, Protein C ve protein S sistemleri, Doku plazminojen aktivatörü,
fibrinojen
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Introduction
Although cardiopulmonary bypass (CPB) is essential
for most cardiac surgical procedures, it is not a
physiological process because it activates the coagulation
system. This is via a number of mechanisms, including
alterations in the contact factor pathway, fibrinolysis,
platelet function, complement and inflammation. Surgery
itself also activates the tissue factor pathway of
coagulation (1).
Intraoperative and postoperative bleeding is one of
the main complications in patients undergoing CPB for
cardiac surgery (1,2). During CPB, the blood is exposed
to large foreign surfaces and materials, and flow
conditions normally not found in the circulation (2). In
addition, use of homologous blood, pump prime fluids
and heparinization and reversal with protamine introduce
complex changes in hemostasis. All of these factors affect
the platelet function, coagulation and the fibrinolytic
system (3). A variety of hemostatic changes such as
platelet dysfunction, activation of blood coagulation
despite anticoagulation with heparin, inactivation of
clotting factors either by consumption or by residual
effects of heparin after its neutralization by protamine,
and hyperfibrinolysis due to an enhanced release of
tissue-type plasminogen activator (t-PA) are reported (47).
Although routinely administered during CPB, heparin
cannot completely prevent the activation of the
coagulation cascades with a subsequent increase in
thrombin generation (8,9). Prior studies have reported
that CPB results in increased levels of active t-PA in blood
during CPB. Elevated active t-PA during CPB is associated
with an increased rate of fibrinolysis and excessive
bleeding (10-14). Despite its central role in the regulation
of blood coagulation, little is known about the behavior of
the protein C system during CPB. The protein C system
primarily consists of the plasma factors: protein C and S
and the endothelium-bound thrombomodulin (15,16).
Based on epidemiological studies revealing a significant
correlation between thrombin activation and fibrinogen
plasma levels in patients suffering from coronary artery
sclerosis, a hypercoagulable state existing in ischemic
heart disease has been postulated (9,17,18).
To assess whether there is a subclinical activation of
the hemostatic system associated with open-heart
surgery, in vivo molecular markers of hemostatic
activation were determined preoperatively, during, and at
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the end of CPB in operated patients. Therefore, we aimed
to investigate in a randomized in vivo setting the behavior
of the protein C and protein S system, t-PA and
fibrinogen during CPB in patients with elective coronary
artery bypass grafting (CABG).
Materials and Methods
Human Subjects
The study was carried out on 33 patients (27 male, 6
female, range 35-69 years of age) who underwent
elective CABG and on 11 patients (7 male, 4 female,
range 28-65 years of age) who underwent non-cardiac
surgery in Atatürk University Cardiovascular Surgery
Department. All the patients were informed and all
provided written consent. Patients with bleeding diathesis
and impaired renal function were not included in the
study group. The control patients were free from
arteriosclerosis.
In all patients, CPB was accomplished following
general
anesthesia,
median
sternotomy
and
heparinization. Before cannulation, bovine heparin (3
mg/kg) was administered. The CPB was maintained with
a non-pulsatile blood flow with a rate of 2.2 L/m2/min
during moderate hypothermia (30° to 32° C).
Cardioplegia was achieved with ice-cold crystalloid
cardioplegia (Plegisol, Abbot) infused in the ascending
aorta after clamping the aorta. The CPB circuit consisted
of a venous reservoir (Baxter, Bentley, Irvine, CA, USA),
an arterial line filter (Affinity arterial filter), a roller-pump
(Sarns 3M, Ann Arbor, Michigan, USA), and a membrane
oxygenator (Oxim-II 34 and RV 40 Macchi, Braile
Biomedica, Brazil). Heparin was neutralized with
protamine sulfate in a 1:1 ratio with the initial heparin
dose following completion of CPB.
Blood Sampling and Assays
Blood samples were taken from a central venous line
in the preoperative period, after induction of anesthesia,
3 min after onset of CPB, after release of aortic crossst
clamp (CC), after completion of CPB, and at the 1 and
th
24 hours after arrival in the intensive care unit in the
study group. Blood samples were taken in the
preoperative, operative and postoperative periods in the
control group. The samples were collected in tubes
containing sodium citrate. For the measurement of
parameters, blood was collected in 10 ml tubes
containing 1.5 mg/ml ethylenediaminetetraacetate and 50
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Figure 1.

Protein C levels decreased after heparinization and
start of CPB. They remained low close to the end of CPB,
and then rose postoperatively (Figure 1).
Table 1. Patient characteristics and operative parameters.
35-69
6/27
1.67-1.98
39-97
80-164

BSA: Body-weight surface area. CPB: Cardiopulmonary bypass.
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Protein C, Protein S, t-PA and Fibrinogen Levels

Plasma concentrations of protein C in the patients
undergoing CPB surgery.

The course of protein S levels resembled that seen for
protein C: a sharp decrease after heparinization and start
of CPB, remaining low until the end of CPB, after which
protein S began to rise but remained lower compared to
baseline. Protein S levels began to increase at the end of
CPB and continued to rise in the early postoperative
period (Figure 2).

Results
Thirty-three patients who underwent elective CABG
were included in the study (27 male, 6 female, range 3569 years of age). The characteristics of patients and
operative parameters are presented in Table 1. There
were 11 patients in the control group (7 male, 4 female,
range 28-65 years of age) who were free from
arteriosclerosis and underwent non-cardiac surgery. The
perioperative course of the patients was uneventful. No
major complications occurred.
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The statistical software package SPSS 9.0 for
Windows (SPSS Inc.) was used for all analyses. Data were
expressed as a mean ± standard error of the mean. Twoway analysis of variance for repeated measures was used
for comparisons of variables measured over time
between the preoperative and postoperative parameters.
Data were further calculated by one-way analyses of
variance for each parameter and groups. The results were
considered significant if the p value was less than 0.05.
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Statistical Analysis

Age (years)
Sex (female/male)
BSA (m2)
Cross-clamp (min)
CPB time (min)
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Protein C was measured by enzyme-linked
immunosorbent assay (ELISA) (Diagnostic Stago, France).
Protein S was measured by ELISA. t-PA was measured by
solid phase sandwich ELISA method (Diagnostic Stago,
France). A nephelometric method was used to measure
®
the concentration of fibrinogen (Fibriquik kit) in plasma
(Dade Behring); the functional fibrinogen levels were
measured using Multifibrin U (Dade Behring).

%

U/ml aprotinin. The samples were centrifuged at 3,000
rpm for 10 min at 4 °C, and the plasma obtained was
stored at –80 °C until assay.
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Plasma concentrations of protein S in the patients
undergoing CPB surgery.

Within 3 min after starting CPB, t-PA levels began to
increase. Before releasing aortic CC, t-PA levels had
increased about eight-fold compared to baseline
(p<0.001). Peak t-PA levels occurred about 40 min into
CPB. At the end of CPB, t-PA levels began to decrease and
the decrease continued in the early postoperative period
(Figure 3). Postoperative plasma concentrations of t-PA
were higher in comparison to preoperative
concentrations (p<0.05).
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After onset of CPB, fibrinogen levels decreased
significantly. On average, fibrinogen levels remained low
close to the end of CPB. During the postoperative period,
a significant increase was observed in all patients (Figure
4).
The plasma levels of protein C, protein S, t-PA and
fibrinogen were compared prior to starting CPB, during
CPB, and in the postoperative period. Postoperative
plasma levels of t-PA were higher, while postoperative
plasma levels of protein C, protein S and fibrinogen were
lower in comparison to their preoperative concentrations
(p<0.01). During the CPB, an increase in the plasma
levels of t-PA was observed, while plasma levels of
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protein C, protein S and fibrinogen decreased (p<0.05,
Figures 1-4).
Hematocrit (Htc) levels were 20 to 25% used during
CPB, while they were normal in the control group. No
differences were observed in hemostatic markers in the
control group. There were statistically significant
differences between the groups (p<0.01) before the
induction of anesthesia and during CPB for all parameters
(p<0.01).

Discussion
Despite extensive investigation, the underlying basis
of hemorrhagic and thrombotic diatheses associated with
CPB is not well characterized. Defective hemostasis
during and following CPB is most likely caused by a
combination of multiple factors, including a platelet
function defect, thrombocytopenia, activation of
coagulation,
and
a
fibrinolytic
state
(13,6,7,12,13,19,20).
Fibrinolytic activity increases significantly during and
following CPB and contributes to the hemostatic defect
causing increased postoperative blood loss (2,13,20).
This results from activation of fibrinolysis by systemic
high-dose heparin as well as inhibition of _ 2-antiplasmin
(an inhibitor of fibrinolysis) and the release of t-PA due to
kallikrein production with the commencement of CPB (1).
A variety of hemostatic changes such as
hyperfibrinolysis are due to an enhanced release of t-PA
(6,7,10,14). Augmented fibrinolytic activity during CPB
is related to the increased levels of t-PA (21). This
situation is related to the high bleeding tendency.
The natural anticoagulant system, which is activated
as a consequence of thrombin generation, represents the
thrombomodulin-protein C system. Protein C, which
modulates coagulation at the blood-endothelial
interphase, is an important physiologic anticoagulant.
Protein S is a necessary cofactor for the action of protein
C. It participates in the formation of a complex containing
protein S and activated protein C (3,5,7,9,15-18,22). A
decrease in protein C and protein S levels with a
subsequent rise in soluble thrombomodulin during CPB
was described previously (3,9). In the present study, we
observed that protein C and protein S levels decreased at
all intervals studied during CPB. These results suggest
that despite heparin administration during CPB, the
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protein C and protein S system is directly or indirectly
activated by thrombin. Circulating thrombin rapidly binds
to thrombomodulin expressed on the endothelial surface
and enhances protein C activation more than 1000-fold
(3,5,9,15). Maruyama (18) have shown that activated
protein C not only inactivates clotting factors Va and
VIIIa, but may also be involved in the induction of
fibrinolysis.

While the early increase in t-PA and thrombin
generation may be related, the continued high secretion
of t-PA during the postoperative period appears to be due
to some other mechanisms. The immediate early increase
in t-PA levels may be due to stimulated release of stored
t-PA from the endothelium, with the sustained increase in
secretion due to an acute-phase increase in t-PA
production (14).

This study was performed to elucidate the patterns of
protein C, protein S, t-PA and fibrinogen activation
during CPB in patients with CABG. The protein C, protein
S, t-PA and fibrinogen levels were significantly different
between the groups. Since Htc levels were 20 to 25%
used during CPB, most of the reduction in the hemostatic
markers appears to be due to dilution. However,
hemostatic markers continued to differ at the end of CPB
and into the postoperative period, while Htc levels were
normal.

In the Northwick Park Heart Study, a strong
association between plasma levels of fibrinogen and
clotting factors VII and VIII and the risk of coronary
sclerosis was demonstrated. A significant correlation
between thrombin activation and fibrinogen plasma levels
was established (9,17,18). In accordance with these
results, coronary artery bypass patients in our study
demonstrated significantly lower fibrinogen levels during
CPB.

At the onset of CPB, we found sharp decreases in
protein C and protein S levels, which persisted through
the remainder of the procedure. These findings are in
accordance with the results of Speekenbrink and
colleagues (15). Protein S, protein C and fibrinogen
values during the CPB showed an important decrease, as
in other studies (3,5,7,9,21). Protein C showed its effect
by rapidly removing the present thrombin from blood
circulation (23). During the CPB, protein C plasma level
showed an important decrease and this had an important
role in the activation of the blood coagulation mechanism.
t-PA levels were increased mildly during early surgery
prior to the initiation of CPB, and then increased eightfold during CPB, while protein S, protein C and fibrinogen
levels remained low. t-PA levels remained elevated
throughout the remainder of CPB, resulting in continued
high levels of active t-PA. For the remainder of CPB and
in the postoperative period, t-PA remained at high levels.
Numerous studies have shown that t-PA values are
increased during CPB (2,10,14,24), as in our study.
The cause of the increase in t-PA secretion during CPB
is unknown. A variety of factors can stimulate t-PA
secretion in vivo and in vitro including thrombin,
bradykinin, epinephrine and vasopressin. Numerous
studies have shown that thrombin generation is increased
during CPB, and it has been suggested that increased tPA secretion and hyperfibrinolysis during CPB might in
part be due to increased thrombin generation
(2,10,14,24,25).

In our study, t-PA levels after induction were
significantly higher in the CABG group and remained at a
higher level throughout the entire investigation period
(9,26), and fibrinogen levels were markedly reduced.
These changes reflect endothelial dysfunction in
arteriosclerosis associated with impaired anticoagulant
properties contributing to the hypercoagulable state
observed in coronary artery disease.
The values of all parameters in this study showed a
statistical difference (p<0.05, Figures 1-4) compared to
baseline. These results suggest that activation of
coagulation was prior to the activation of fibrinolysis.
Teufelsbauer and colleagues (2) concluded that patients
undergoing CABG may be at a special risk for
thromboembolic complications due to increased thrombin
generation during CPB leading to hypercoagulability in
the early postoperative period, which may be complicated
by reactive hyperfibrinolysis.
Coronary artery bypass patients as well are
threatened by thromboembolic complications such as
myocardial infarction and stroke, which can partly be
explained by the pre-existing hemostatic changes and an
increased procoagulant activity in the perioperative
period. Furthermore, based on the underlying disease,
coronary artery bypass patients showed a higher degree
of endothelial damage contributing to the impaired
anticoagulant properties of the endothelium. A number of
different techniques, including heparin-coated bypass
circuits, off-pump heart surgery and drugs such as
aprotinin and ε-amino caproic acid, may be used to
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suppress enhanced fibrinolysis and
inflammatory state associated with CPB.
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reduce

the

In conclusion, the results from this study provide
evidence for activation of the protein C and protein S
system, t-PA and fibrinogen during CPB. Use of various

Turk J Med Sci

hemostatic markers to estimate the underlying rate of
processes in vivo may be used to evaluate the effect of
these activations in future studies. The effect of CPB on
hemostasis requires further investigations.
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